MedTrace Logo

Tigecycline for Treatment of Rapidly Growing Mycobacteria

NCT00600600 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2017-05-23

No results posted yet for this study

Summary

To determine the safety, tolerance, and efficacy of Tigecycline when given daily to patients with rapidly growing mycobacterial disease (especially M.abscessus).

Conditions

  • Mycobacterium Abscessus Lung Disease
  • Rapidly Growing Mycobacterial Lung Disease

Interventions

DRUG

Tigecycline

Tigecycline dosage based on age and clinical status of patient.

Sponsors & Collaborators

  • Wyeth is now a wholly owned subsidiary of Pfizer

    collaborator INDUSTRY

  • The University of Texas Health Science Center at Tyler

    lead OTHER

Principal Investigators

  • Richard J Wallace Jr., M.D. · The University of Texas Health Science Center at Tyler

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-04-30
Primary Completion
2010-04-30
Completion
2010-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00600600 on ClinicalTrials.gov